Cancers, Vol. 13, Pages 5210: Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article

Cancers, Vol. 13, Pages 5210: Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article Cancers doi: 10.3390/cancers13205210 Authors: Arthur Bobin Cécile Gruchet Stéphanie Guidez Hélène Gardeney Laly Nsiala Makunza Mathilde Vonfeld Anthony Lévy Laura Cailly Florence Sabirou Thomas Systchenko Niels Moya Xavier Leleu Novel treatments are needed to address the lack of options for patients with relapsed or refractory multiple myeloma. Even though immunotherapy-based treatments have revolutionized the field in recent years, offering new opportunities for patients, there is still no curative therapy. Thus, non-immunologic agents, which have proven effective for decades, are still central to the treatment of multiple myeloma, especially for advanced disease. Building on their efficacy in myeloma, the development of proteasome inhibitors and immunomodulatory drugs has been pursued, and has led to the emergence of a novel generation of agents (e.g., carfilzomib, ixazomib, pomalidomide). The use of alkylating agents is decreasing in most treatment regimens, but melflufen, a peptide-conjugated alkylator with a completely new mechanism of action, offers interesting opportunities. Moreover, with the identification of novel targets, new drug classes have entered the myeloma armamentarium, such as XPO1 inhibitors (selinexor), HDAC inhibitors (panobinostat), and anti-BCL-2 agents (venetoclax). New pathways are still being e...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research